Late termination of pregnancy at a major Queensland tertiary hospital, 2010-2020.

OBJECTIVE: To review rates of and indications for late pregnancy feticide at a major Queensland tertiary perinatal centre over the past decade. DESIGN: Retrospective cohort study. SETTING, PARTICIPANTS: The Centre for Advanced Prenatal Care at the Royal Brisbane and Women's Hospital, a tertiary perinatal centre; feticides of singleton pregnancies of at least 22 weeks' gestation, 1 January 2010 - 31 December 2020. MAIN OUTCOME MEASURES: Indications for feticide; median gestational age at feticide; referral source; time between referral, maternal-fetal medicine review, and feticide. RESULTS: During 2010-2020, 305 feticides were undertaken at 22 weeks' gestation or later. The annual number of feticides increased from 20 in 2010 to 54 in 2020. The median gestational age at feticide was consistent across the decade (24+6 weeks; range, 17+0 to 37+1 weeks). The most frequent fetal indications for feticide were neurological abnormalities (110 of 305, 36%), aneuploidy or genetic syndromes (67, 22%), and cardiac malformations (59, 19%). Most women were seen for review within seven days of referral for feticide (154 of 197 for whom this information was available, 78%; median, five days; range, 0-34 days), and 136 of 197 feticides (69%) were undertaken within seven days of the initial maternal-fetal medicine review. CONCLUSIONS: Most late pregnancy feticides were performed because of fetal indications, primarily structural malformations or genetic abnormalities. Despite advances in prenatal imaging and diagnosis, late termination of pregnancy remains a necessary option in some pregnancies with maternal or fetal indications, and equitable access to late termination of pregnancy services is a vital component of reproductive health care.

Termination of pregnancy for maternal medical indications: failings in delivery of contraceptive advice?

BACKGROUND: The majority of therapeutic terminations of pregnancy occur for maternal psychological, social or fetal reasons. Available data on maternal medical indications, rather than social, are sparse. AIMS: To examine the maternal medical indications for the termination of pregnancy and use of contraception over a ten-year period. METHODS: A retrospective review of cases of termination of pregnancy performed for maternal indications in an Australian tertiary obstetric referral hospital. Cases from January 2000 to July 2010 inclusive were selected by examination of a termination of pregnancy database at our hospital. RESULTS: From 893 terminations, 104 were performed for maternal indications and had notes available for review: mean maternal age, 28.2 years (SD, 6.6; range, 14-44); median gravidity, 2; and parity, 1; and mean gestational age, 11.5 weeks (SD, 4.6; range, 5-23). Terminations were primarily surgical (n=81 (78.6%)) rather than by induction of labour (n=22 (21.4%)). Frequent maternal indications included psychiatric (n=24 (23.1%)), malignancy (n=17 (16.3%)) and cardiac (n=13 (12.5%)). Information on contraceptive use prior to termination was available in 40 (53%) women known to have disease prior to conception. Contraception was recorded as being in use prior to conception in 19 (47.5%) of these. Following termination, 75 (75.7%) were recorded as using contraception. CONCLUSIONS: Contraceptive rates in this at risk group appear to be poor and require attention.

-455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications.

Hyperfibrinogenaemia is associated with systemic arterial and venous thromboembolism and therefore may contribute to placental vascular disease associated with obstetric complications. The fibrinogen-raising -455G/A beta-fibrinogen gene polymorphism may enhance the physiological increase in fibrinogen levels during pregnancy and thereby predispose to obstetric complications. This retrospective case-control study looked at the association between the beta-fibrinogen gene polymorphism -455G/A, the hereditary thrombophilic markers factor V Leiden, prothrombin G20210A mutation (PGM) and C677T methylene tetrahydrofolate reductase (MTHFR), and obstetric complications associated with placental vascular disease. The study group (n = 247) comprised 147 women (90 Caucasian) who met the clinical criteria and a control group of 100 parous women (90 Caucasian) with no history of obstetric or medical complications. No significant differences were observed in the -455A allelic frequencies of the patient and normal control groups, with (allelic frequencies, 0.156 and 0.178, respectively; P = 0.5716, chi2 test, odds ratio = 1.17, 95% confidence interval = 0.65-2.13) or without (allelic frequencies, 0.129 and 0.170, respectively; P = 0.2077, chi2 test, odds ratio = 1.38, 95% confidence interval = 0.81-2.35) the exclusion of non-Caucasian women. There was an increased prevalence of factor V Leiden among Caucasian patients compared with normal controls (allelic frequencies, 0.056 and 0.017, respectively; P = 0.048, chi2 test, odds ratio = 0.29, 95% confidence interval = 0.05-1.15) but there were no differences in the prevalences of PGM or MTHFR. These data suggest that factor V Leiden is associated with an increased risk of obstetric complications, but that the -455A allele of beta-fibrinogen, PGM and MTHFR do not appear to be implicated.